ScreenerHero

AEON AEON Biopharma, Inc.

AMEX · US · Healthcare · Biotechnology · aeonbiopharma.com
0.3113USD+7.44%Mkt Cap: 15.53M $P/E: —

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 st…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap15.53M USD
Enterprise Value13.80M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-39.22M USD
Revenue/Share—
Last Price0.3113 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees8
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.14
PEG—
EV/EBITDA-0.70
EV/Revenue—
P/S—
P/B-0.50
EPS (TTM)-4.71
EPS (Forward)-0.25
52W Range
0.179710% of range1.450
52W High1.450 USD
52W Low0.1797 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE71.28%
ROA-705.43%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-17.31M USD
CapEx (TTM)4.00K USD
FCF Margin—
FCF Yield-46.29%
Net Debt-656.00K USD
Net Debt/EBITDA0.03
Balance Sheet
Debt/Equity-0.65
Current Ratio0.54
Quick Ratio0.47
Book Value/Sh-0.58 USD
Cash/Share0.07 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:72
Split DateFeb 26, 2025
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)1.820 USD
Upside (mean)+484.7%
Target Range1.200 USD – 2.100 USD
1.200+484.7% to mean2.100
# Analysts5
Ownership
Shares Out.49.88M
Float24.01M
Insiders54.98%
Institutions32.77%
Short Interest
Short Ratio0.2d
Short % Float7.85%
Short % Out.5.91%
Shares Short2.95M
Short (prev mo.)1.13M
Technical
SMA 500.2631 (+18.3%)
SMA 2000.7554 (-58.8%)
Beta0.69
S&P 52W Chg16.45%
Avg Vol (30d)5.90M
Avg Vol (10d)13.11M
Technical Indicators
RSI (14)54.2
MACD-0.0086
MACD Signal-0.0199
MACD Hist.+0.0113
BB Upper0.3238 USD
BB Middle0.2683 USD
BB Lower0.2128 USD
BB Width41.38%
ATR (14)0.0424 USD
Vol Ratio (20d)0.33x